«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 08

Page:

1512-1518

Research Field:

Publishing date:

Info

Title:

Cancer burden among the elderly in China from 2005 to 2016

Author(s):

LUO Rong¹; MA Xiaoping²; CHEN Lei¹

1.Minhang Branch of Shanghai Fudan University Affiliated Cancer Hospital,Shanghai 201100,China;2.The First Affiliated Hospital of Xinjiang Shihezi University,Xinjiang Shihezi 832000,China.

Keywords:

elderly; cancer; burden of disease; DALY; Joinpoint model

PACS:

R73-31

DOI:

10.3969/j.issn.1672-4992.2024.08.025

Abstract:

Objective:Cancer burden in the aged 60 years and above was evaluated quantitatively,to provide epidemiological evidence for the prevention and control of cancer in China.Methods:In this study,the morbidity and mortality data of cancer patients aged 60 years and above were collected from the China Annual Report of Cancer Registration in 2008-2019.Disability adjusted of life years (DALY) were calculated to analyze the disease burden.The Joinpoint model was used to analyze its time trends.Results:From 2005 to 2016,there were 25 921 678 person-years of DALY caused by cancer in the elderly in China,and the DALY rate fluctuated between 73.43‰ and 84.07‰,decreasing at an average annual rate of 1.2% (95%CI:0.8%~1.5%).The cancer with the largest life loss among the elderly was lung cancer,with an average annual life loss of 28 454 person-years,followed by gastric,liver,esophageal and colorectal cancer in 2005-2016.The life loss caused by the above five cancers accounted for 74.3% of all cancers.The DALY rate of lung cancer in females aged ≥85 years increased with time (AAPC=1.8%，95%CI:0.7%~2.9%).Breast cancer ranked in the top five only in females aged 60~64 years,and the DALY rate also showed an increasing trend (AAPC=2.2%,95%CI:1.3%~3.0%).As people age,the burden from liver cancer decreased and that from colorectal cancer increased.Conclusion:From 2005 to 2016,the cancer disease burden among the elderly in China was decreased,and there were differences in age,gender,region and type of cancer.Therefore,the relevant departments should continue to target the distribution characteristics of different cancer,take more precise preventive and control measures,and rationally allocate health resources to achieve the goal of more effectively reducing the disease burden of cancer.

References:

［1］BRAY F,LAVERSANNE M,WEIDERPASS E,et al.The ever-increasing importance of cancer as a leading cause of premature death worldwide［J］.Cancer，2021，127:3029-3030.
［2］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians，2021，71(3):209-249.
［3］ZHENG R,ZHANG S,ZENG H,et al.Cancer incidence and mortality in China,2016［J］.Journal of the National Cancer Center，2022，2(1):1-9.
［4］项鑫,王乙.中国人口老龄化现状、特点、原因及对策［J］.中国老年学杂志,2021,41(18):4149-4152. XIANG X,WANG Y.Current situation,characteristics,causes and countermeasures of population aging in China［J］.Chinese Journal of Gerontology,2021,41(18):4149-4152.
［5］张学飞,闫贻忠,庞丽娟,等.中国老年人群恶性肿瘤疾病负担［J］.中国老年学杂志,2017,37(21):5325-5329. ZHANG XF,YAN YZ,PANG LJ,et al.Disease burden of malignant tumors in the Chinese elderly population［J］.Chinese Journal of Gerontology,2017,37(21):5325-5329.
［6］马明辉,韩月红.1990年以来中国各地域老年人死因变动情况分析［J］.中国卫生标准管理,2021,12(03):16-19. MA MH,HAN YH.Analysis of changes in causes of death among the elderly in China by geographic region since 1990［J］.China Health Standards Management,2021,12(03):16-19.
［7］赵平,陈万青.2008年中国肿瘤登记年报［M］.北京:军事医学科学出版社,2009:19-151. ZHAO P,CHEN WQ.China cancer registry annual report,2008［M］.Beijing:Military Medical Science Press,2009:19-151.
［8］赵平,陈万青.2009年中国肿瘤登记年报［M］.北京:军事医学科学出版社,2010:16-109. ZHAO P,CHEN WQ.China cancer registry annual report,2009［M］.Beijing:Military Medical Science Press,2010:16-109.
［9］赵平,陈万青.2010年中国肿瘤登记年报［M］.北京:军事医学科学出版社,2011:16-115. ZHAO P,CHEN WQ.China cancer registry annual report,2010［M］.Beijing:Military Medical Science Press,2011:16-115.
［10］赫捷,赵平,陈万青.2011年中国肿瘤登记年报［M］.北京:军事医学科学出版社,2012:16-129. HE J,ZHAO P,CHEN WQ.China cancer registry annual report,2011［M］.Beijing:Military Medical Science Press,2012:16-129.
［11］赫捷,赵平,陈万青.2012年中国肿瘤登记年报［M］.北京:军事医学科学出版社,2013:18-153. HE J,ZHAO P,CHEN WQ.China cancer registry annual report,2012［M］.Beijing:Military Medical Science Press,2013:18-153.
［12］赫捷,陈万青.2013年中国肿瘤登记年报［M］.北京:清华大学出版社,2014:44-219. HE J,CHEN WQ.China cancer registry annual report,2013［M］.Beijing:Tsinghua University Press,2014:44-219.
［13］赫捷,陈万青.2014年中国肿瘤登记年报［M］.北京:清华大学出版社,2015:48-241. HE J,CHEN WQ.China cancer registry annual report,2014［M］.Beijing:Tsinghua University Press,2015:48-241.
［14］赫捷,陈万青.2015年中国肿瘤登记年报［M］.北京:清华大学出版社,2016:52-235. HE J,CHEN WQ.China cancer registry annual report,2015［M］.Beijing:Tsinghua University Press,2016:52-235.
［15］赫捷,陈万青.2016年中国肿瘤登记年报［M］.北京:清华大学出版社,2017:58-241. HE J,CHEN WQ.China cancer registry annual report,2016［M］.Beijing:Tsinghua University Press,2017:58-241.
［16］赫捷,陈万青.2017年中国肿瘤登记年报［M］.北京:清华大学出版社,2018:45-229. HE J,CHEN WQ.China cancer registry annual report,2017［M］.Beijing:Tsinghua University Press,2018:45-229.
［17］赫捷,陈万青.2018年中国肿瘤登记年报［M］.北京:清华大学出版社,2019:47-231. HE J,CHEN WQ.China cancer registry annual report,2018［M］.Beijing:Tsinghua University Press,2019:47-231.
［18］赫捷,陈万青.2019年中国肿瘤登记年报［M］.北京:清华大学出版社,2020:59-251. HE J,CHEN WQ.China cancer registry annual report,2019［M］.Beijing:Tsinghua University Press,2020:59-251.
［19］FREYBERGER H,SCHULTE-MARKWORT E,DILLING H.WHO crosswalk for the tenth revision of the international classification of diseases,chapter V (F):ICD-10 vs.ICD-9［J］.Fortschr Neuro Psyc,1993，61:109-127.
［20］DEVLEESSCHAUWER B,HAVELAAR AH,MAERTENS DE NOORDHOUT C,et al.DALY calculation in practice:a stepwise approach［J］.Int J Public Health,2014，59(3):571-574.
［21］WHO.WHO methods and data sources for global burden of disease estimates 2000-2019［M］.Geneva:WHO,2020:6-10.
［22］雷少元,郑荣寿,魏文强.伤残权重在恶性肿瘤疾病负担研究中的进展［J］.中华肿瘤杂志,2021,43(7):756-761. LEI SY,ZHENG RS,WEI WQ.Advances in disability weights in the study of disease burden of malignancy［J］.Chinese Journal of Oncology,2021,43(7):756-761.
［23］中国国家统计局.中国第五次全国人口普查［EB/OL］.［2023-01-22］.http://www.stats.gov.cn/sj/pcsj/rkpc/5rp/index.htm. National Bureau of Statistics China.The fifth national population census［EB/OL］.［2023-01-22］.http://www.stats.gov.cn/sj/pcsj/rkpc/5rp/index.htm.
［24］KIM HJ,FAY MP,FEUER EJ,et al.Permutation tests for joinpoint regression with applications to cancer rates［J］.Stat Med,2000，19(3):335-351.
［25］张爽,沈成凤,张辉,等.2014年天津市恶性肿瘤流行情况及疾病负担分析［J］.中国肿瘤,2019,28(3):167-174. ZHANG S,SHEN CF,ZHANG H,et al.Analysis of malignant tumor prevalence and disease burden in Tianjin in 2014［J］.China Oncology,2019,28(3):167-174.
［26］GUO H,LIN K,YANG K,et al.Trends of cancer incidence among Chinese older adults from 2005 to 2016:A log-linear regression and age-period-cohort analysis［J］.Front Public Health,2022，10:1023276.
［27］ZHAO Y,TANG S,MAO W,et al.Socio-economic and rural-urban differences in healthcare and catastrophic health expenditure among cancer patients in China:Analysis of the China health and retirement longitudinal study［J］.Front Public Health,2022，9:779285.
［28］WANG H,HUA X,YAO N,et al.The urban-rural disparities and associated factors of health care utilization among cancer patients in China［J］.Front Public Health,2022，10:842837.
［29］CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016，66(2):115-132.
［30］MIYAHARA R,NIWA Y,MATSUURA T,et al.Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population:data from a single institute over 30 years［J］.J Gastroenterol Hepatol,2007，22:1435-1442.
［31］夏锋,李雪松.肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)［J］.临床肝胆病杂志,2020,36(03):514-518. XIA F,LI XS.Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)［J］. Journal of Clinical Hepatol,2020,36(03):514-518.
［32］TAKENAMI T,TSUJINAKA S,TAKAHASHI J,et al.Efficacy of neoadjuvant chemotherapy with capecitabine plus oxaliplatin in the treatment of locally advanced sigmoid colon cancer invading the urinary bladder:a report of three cases［J］.Case Rep Surg,2019，2019:8129358.
［33］SCHMOLL HJ,TABERNERO J,MAROUN J,et al.Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer:Final results of the NO16968 randomized controlled phase III trial［J］.J Clin Oncol,2015，33:3733-3740.
［34］CHEN W,ZHENG S.Incidence,mortality and survival analysis of breast cancer in China［J］.Chinese Journal of Clinical Oncology,2015，13:668-674.

Memo

Memo:

-

Common functions

Last Update: 1900-01-01